Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
ID:
Password:
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

Agents/Distributors
 Regional Subscription Agents/Distributors
 
Current Trends in Neurology   Volumes    Volume 8 
Abstract
L-DOPA/melatonin combination as an alternative Parkinson disease treatment
Verónica Anaya-Martínez, Ana Luisa Gutiérrez-Valdez, José Luis Ordóñez-Librado, Javier Sanchez-Betancourt, Enrique Montiel-Flores, Leonardo Reynoso-Erazo, Rocío Tron-Alvarez, Maria Rosa Avila-Costa
Pages: 87 - 104
Number of pages: 18
Current Trends in Neurology
Volume 8 

Copyright © 2014 Research Trends. All rights reserved

ABSTRACT
 
Parkinson disease (PD) is a neurodegenerative disorder that affects movement due to the progressive degeneration of dopaminergic neurons of the substantia nigra pars compacta (SNc). L-DOPA is the most common drug for the treatment of PD because of its clinical efficacy. However, long-term treatment frequently induces the development of L-DOPA-induced dyskinesias (LID). Several evidences suggest that L-DOPA can increase the pre-existing condition of oxidative stress and for this reason in the present study we combine the L-DOPA-treatment with melatonin, considering the latter as an antioxidant. Hence, we conducted the present study to determine the ability of melatonin alone or melatonin in combination with L-DOPA to protect nigrostriatal dopaminergic loss and motor impairment induced by 6-OHDA (6-hydroxydopamine) in a rat model of PD, comparing the results with L-DOPA-alone treated rats. 36 Wistar rats were stereotactically injected with either 6-OHDA or vehicle. 48 hrs after the lesion, circling behavior was evaluated. Two days after the evaluation, the rats were treated with L-DOPA (7.5 mg/kg; n = 5), or co-administrated with L-DOPA/melatonin (10 mg/kg; n = 5) orally for 6 months, and 5 lesioned rats without treatment were kept for the same time. Motor behavior was evaluated by means of the stepping ability while walking on beams and the severity of LIDs were assessed using measures of abnormal involuntary movements (AIMs). At the cellular level, the number of TH-positive immune cells and dendritic spines of the striatal medium-size spiny neurons were evaluated. Our results show that the rats with the co-administration of L-DOPA/melatonin had the best performance in the motor tasks and decreased LIDs, through the increase in the number of dopaminergic cells and the conservation of dendritic spines, which in turn imply a well-preserved synaptology of a less denervated striatum. Our results suggest that the co-administration of L-DOPA/melatonin could be a possible candidate for the treatment of PD to prevent or slow the damage caused by L-DOPA.
Buy this Article


 
search


E-Commerce
Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Login
Search Products
Browse in Alphabetical Order : Journals
Series/Books
Browse by Subject Classification : Journals
Series/Books

Miscellaneous
Ordering Information Ordering Information
Downloadable forms Downloadable Forms